Ensoma is a biotechnology company focused on developing potentially curative medicines for genetic diseases, immune disorders, and cancer through in vivo hematopoietic stem cell (HSC) engineering. Utilizing proprietary base editing and high-efficiency gene integration systems, Ensoma's platform employs high-capacity virus-like particles (VLPs) to deliver genetic payloads directly to HSCs, enabling one-time administration of durable genetic therapies. The company is advancing its clinical-stage pipeline, including a Phase 1/2 trial for EN-374 targeting X-linked chronic granulomatous disease, and aims to make a global impact in the field of genetic medicines.
Leadership & Board
Currently, no data available
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$53M
Total Amount Raised$53M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$53M
Latest Funding Amount$53M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.